MarketPeel
Insider Trading Intelligence
GW

Gregory L. Weaver

ATOS
FORMER EVP, CFO, & DIRECTOR · ATOSSA THERAPEUTICS, INC. · CIK 0001251779
FILING MIX · LIFETIME74%/26%
BUYS
23
SELLS
8
TOTAL VALUE
$1.61M
COMPANIES
3
ACTIVE SINCE
May 2020
HOLDINGS NOW
266,133
AVG SELL PX
$4.64
TRADE KIND
SHOWING 31 / 31
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
7 backtested trades · 8 horizons · 7 pending
Forward-return performance of every backtestable P/S trade by Gregory L. Weaver, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d7+42.86%+4.26%+0.95%+3.31%+0.37%
14d7+57.14%+5.24%+1.54%+3.70%+2.15%
30d7+28.57%-7.48%+2.45%-9.93%-11.21%
60d7+28.57%-2.63%+4.81%-7.51%-13.97%
90d7+28.57%-3.39%+6.13%-6.91%-18.72%
180d7(2 pending)+20.00%-11.28%+12.57%-23.84%-45.60%
1y7(2 pending)+40.00%-13.75%+11.98%-25.73%-53.16%
2y7(3 pending)+25.00%-40.40%+26.03%-66.43%-68.73%
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
ATOS · 55 shares · as of Nov 15, 2023
0650,0001,300,0001,950,0002,600,000202120222023SHARES HELD
Trading cadence · quarterly flow
BUY SELL
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 23 buys / 8 sellsCOVERAGE · 25 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
ALT
ALTIMMUNE, INC.
PURCHASE
Chief Financial Officer
10,000$3.15$31.5K38,078Apr 1, 2026Apr 1, 2026View →
ALT
ALTIMMUNE, INC.
PURCHASE
Chief Financial Officer
5,000$3.54$17.7K28,078Mar 6, 2026Mar 9, 2026View →
ALT
ALTIMMUNE, INC.
PURCHASEGRANT
Stock grant
259,000259,000Feb 26, 2026Feb 27, 2026View →
ALT
ALTIMMUNE, INC.
PURCHASEGRANT
Stock grant
111,000111,000Feb 26, 2026Feb 27, 2026View →
ALT
ALTIMMUNE, INC.
SALE
Chief Financial Officer
18,75056,250Nov 11, 2025Nov 12, 2025View →
ALT
ALTIMMUNE, INC.
PURCHASE
Chief Financial Officer
18,75028,750Nov 11, 2025Nov 12, 2025View →
ALT
ALTIMMUNE, INC.
SALE
Chief Financial Officer
5,672$4.28$24.3K23,078Nov 11, 2025Nov 12, 2025View →
ALT
ALTIMMUNE, INC.
PURCHASEGRANT
Stock grant
57,90057,900Oct 1, 2025Oct 3, 2025View →
ALT
ALTIMMUNE, INC.
PURCHASEGRANT
Stock grant
166,800166,800Oct 1, 2025Oct 3, 2025View →
ALT
ALTIMMUNE, INC.
PURCHASE
Chief Financial Officer
10,000$5.20$52.0K10,000Mar 13, 2025Mar 14, 2025View →
ALT
ALTIMMUNE, INC.
PURCHASEGRANT
Stock grant
225,000225,000Nov 11, 2024Nov 12, 2024View →
ALT
ALTIMMUNE, INC.
PURCHASEGRANT
Stock grant
75,00075,000Nov 11, 2024Nov 12, 2024View →
ATOS
ATOSSA THERAPEUTICS, INC.
SALE
Former EVP, CFO, & Director
50,000$0.65$32.5K55Nov 15, 2023Nov 17, 2023View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASE
EVP & CFO
50,000$0.97$48.5K50,055Jun 20, 2023Jun 20, 2023View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
2,600,0002,600,000Jun 1, 2023Jun 5, 2023View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
125,000125,000May 4, 2023May 5, 2023View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,00050,000May 13, 2022May 16, 2022View →
ATAI
ATAIBECKLEY INC.
PURCHASEGRANT
Stock grant
228,000228,000Mar 2, 2022Mar 4, 2022View →
ATOS
ATOSSA THERAPEUTICS, INC.
SALE
57,084$6.40$365.3K107,497Jul 2, 2021Jul 7, 2021View →
ATOS
ATOSSA THERAPEUTICS, INC.
SALE
45,0000Jul 2, 2021Jul 7, 2021View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASE
45,000$2.52$113.4K94,581Jul 2, 2021Jul 7, 2021View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASE
45,000$2.38$107.1K49,581Jul 2, 2021Jul 7, 2021View →
ATOS
ATOSSA THERAPEUTICS, INC.
SALE
70,0000Jul 2, 2021Jul 7, 2021View →
ATOS
ATOSSA THERAPEUTICS, INC.
SALE
107,497$5.58$599.8K0Jul 2, 2021Jul 7, 2021View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASE
70,000$1.70$119.0K164,581Jul 2, 2021Jul 7, 2021View →
ATOS
ATOSSA THERAPEUTICS, INC.
SALE
4,5810Jul 2, 2021Jul 7, 2021View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASE
4,581$5.64$25.8K4,581Jul 2, 2021Jul 7, 2021View →
ATAI
ATAIBECKLEY INC.
PURCHASE
Chief Financial Officer
4,666$15.00$70.0K4,666Jun 22, 2021Jun 24, 2021View →
ATAI
ATAIBECKLEY INC.
PURCHASEGRANT
Stock grant
67,72667,726Jun 17, 2021Jun 22, 2021View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
50,00050,000May 14, 2021May 18, 2021View →
ATOS
ATOSSA THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
70,00070,000May 15, 2020May 19, 2020View →
Other insiders · ATOS
Loading peer insiders…
About this filer
CIK 0001251779
ROLE
Former EVP, CFO, & Director
PRIMARY
ATOS
COMPANIES
3
ACTIVE SINCE
May 2020
MARKETPEEL · /INSIDER/0001251779DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback